# China Approved This Lung Cancer Drug. The FDA Is Making Americans Wait.

- URL: https://talkfuse.com/story/china-approved-this-lung-cancer-drug-the-fda-is-making-americans-wait/
- Published: 2026-11-18T12:30:23+00:00
- Updated: 2026-11-18T13:39:25+00:00
- Original publisher: Reason (publisher lean: Right)
- Original article: https://reason.com/2026/11/18/china-approved-this-lung-cancer-drug-the-fda-is-making-americans-wait/
- Topics: Americas, Asia, Health, Medicine, Politics, World

## Key points

- FDA rejected US marketing of ivonescimab for some advanced lung cancer patients.
- A global trial showed delayed progression, but not longer overall survival.
- The article calls for an explanation and meaningful patient choice.

## Summary

China approved ivonescimab in 2024 for some people with advanced lung cancer, but the US Food and Drug Administration has rejected Summit Therapeutics’ application to sell it in the United States. The decision means American doctors cannot routinely offer the drug to patients whose cancer has progressed after targeted treatment, despite trial evidence that it can delay worsening.

In a global trial, ivonescimab with chemotherapy kept cancer in check longer than chemotherapy alone, but did not establish that patients lived longer overall; a separate Chinese trial found a survival benefit. The article compares the decision with the FDA’s 2024 approval of Rybrevant with chemotherapy, which also delayed progression without proven overall survival benefit, while noting different trial results and side effects. It argues that the FDA should explain the distinction and that patients and doctors should be able to weigh treatment trade-offs.

---
Summarised by TalkFuse (https://talkfuse.com/). Quote the original publisher for the reporting and link this page for the summary and discussion.
